Sarepta Therapeutics, Inc. Business Finance Contracts & Agreements
63 Contracts & Agreements
- Credit Agreements (4 contracts)
- Exchange Agreements (1)
- Guarantee Agreements (1)
- Indenture Agreements (2)
- Investment Agreements (1)
- Loan Agreements (1)
- Modification Agreements (2)
- Note Agreements (1)
- Pledge Agreements (1)
- Purchase Agreements (10)
- Registration Rights Agreements (2)
- Release Agreements (2)
- Shareholders Agreements (1)
- Stock Agreements (17)
- Underwriting Agreements (7)
- Warrant Agreements (10)
- Amendment No. 2 to the Sarepta Therapeutics, Inc. Amended and Restated 2013 Employee Stock Purchase Plan (Filed With SEC on June 9, 2023)
- Form of Exchange Agreement (Filed With SEC on March 3, 2023)
- Purchase Agreement, dated as of September 13, 2022, between Sarepta Therapeutics, Inc. and Michael A. Chambers Living Trust (Filed With SEC on September 19, 2022)
- Purchase Agreement, dated as of September 13, 2022, among Sarepta Therapeutics, Inc. and the several Initial Purchasers named in Schedule 1 thereto for whom Goldman, Sachs & Co.... (Filed With SEC on September 19, 2022)
- Indenture, dated as of September 16, 2022, by and between Sarepta Therapeutics, Inc. and U. S. Bank Trust Company, National Association (including the form of the 1.250%... (Filed With SEC on September 19, 2022)
- Underwriting Agreement, October 13, 2021 among Sarepta Therapeutics, Inc. and Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC and Credit Suisse... (Filed With SEC on October 15, 2021)
- First Amendment dated September 24, 2020 to Loan Agreement among Sarepta Therapeutics, Inc., BioPharma Credit PLC and BioPharma Credit Investments V (Master) LP dated December 13,... (Filed With SEC on November 5, 2020)
- Amendment No. 1 to the Sarepta Therapeutics, Inc. Amended and Restated 2013 Employment Stock Purchase Plan (as Amended and Restated on June 27, 2016) (Filed With SEC on August 7, 2019)
- Underwriting Agreement, March 5, 2019 among Sarepta Therapeutics, Inc. and Goldman Sachs & Co. LLC and Morgan Stanley & Co. LLC, as representatives of the underwriters named... (Filed With SEC on March 7, 2019)
- Amendment to Restricted Stock Award Agreement between Douglas S. Ingram and Sarepta Therapeutics, Inc. dated December 17, 2018 (Filed With SEC on February 28, 2019)
- Underwriting Agreement, dated November 8, 2018, among Sarepta Therapeutics, Inc. and Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Credit Suisse Securities (USA) LLC, as... (Filed With SEC on November 9, 2018)
- Warrant to Purchase Common Stock of Myonexus Therapeutics, Inc., issued by Myonexus Therapeutics, Inc. to Sarepta Therapeutics, Inc., dated as of May 3, 2018 (Filed With SEC on August 8, 2018)
- First Amendment to the Credit and Security Agreement, dated November 7, 2017, between the Company and MidCap Financial Trust, as administrative agent (Filed With SEC on November 14, 2017)
- First Amendment to the Amended and Restated Credit and Security Agreement, dated November 7, 2017, between the Company and MidCap Financial Trust, as administrative agent (Filed With SEC on November 14, 2017)
- Indenture, dated as of November 14, 2017, by and between Sarepta Therapeutics, Inc. and U. S. Bank National Association (including the form of the 1.50% Convertible Senior Note... (Filed With SEC on November 14, 2017)
- Purchase Agreement, dated as of November 8, 2017, among Sarepta Therapeutics, Inc. and the several Initial Purchasers named in Schedule 1 thereto for whom J.P. Morgan Securities... (Filed With SEC on November 14, 2017)
- Amended and Restated Credit and Security Agreement between Sarepta Therapeutics, Inc. and MidCap Financial Trust dated July 18, 2017 (Filed With SEC on August 3, 2017)
- 7,650,000 Shares SareptaTherapeutics, Inc. Common Stock ($0.0001 par value) EQUITYUNDERWRITING AGREEMENT (Filed With SEC on July 26, 2017)
- Asset Purchase Agreement dated February 20, 2017 by and between Sarepta Therapeutics Inc. and Gilead Sciences, Inc (Filed With SEC on May 4, 2017)
- 5,020,921 Shares SareptaTherapeutics, Inc. Common Stock ($0.0001 par value) EQUITYUNDERWRITING AGREEMENT (Filed With SEC on September 23, 2016)
- SAREPTA THERAPEUTICS, INC. AMENDED AND RESTATED 2013 EMPLOYEE STOCK PURCHASE PLAN (as Amended and Restated on June 27, 2016) Sarepta Therapeutics, Inc., a Delaware corporation... (Filed With SEC on July 1, 2016)
- 2,102,000 Shares SareptaTherapeutics, Inc. Common Stock ($0.0001 par value) EQUITYUNDERWRITING AGREEMENT (Filed With SEC on June 10, 2016)
- 3,250,000 Shares SareptaTherapeutics, Inc. Common Stock ($0.0001 par value) EQUITYUNDERWRITING AGREEMENT (Filed With SEC on October 6, 2015)
- PLEDGE AGREEMENT (Filed With SEC on August 6, 2015)
- CREDIT ANDSECURITY AGREEMENT (Filed With SEC on August 6, 2015)
- PURCHASE AND SALE AGREEMENT (Filed With SEC on August 7, 2014)
- 2,650,000Shares Sarepta Therapeutics, Inc. Common Stock ($0.0001 par value) EQUITY UNDERWRITING AGREEMENT (Filed With SEC on April 24, 2014)
- SAREPTA THERAPEUTICS, INC. EXECUTIVE INDUCEMENT STOCK OPTION AWARD AGREEMENT (Filed With SEC on March 3, 2014)
- SAREPTA THERAPEUTICS, INC. AMENDED AND RESTATED 2011 EQUITY INCENTIVEPLAN STOCK OPTION AWARD AGREEMENT (Filed With SEC on August 8, 2013)
- SAREPTA THERAPEUTICS, INC. AMENDED AND RESTATED 2011 EQUITY INCENTIVEPLAN NOTICE OF GRANT OF RESTRICTED STOCK (Filed With SEC on August 8, 2013)
- Signature(s) Guaranteed: Medallion Guarantee Stamp (Filed With SEC on August 8, 2013)
- SAREPTA THERAPEUTICS, INC. Common Stock ($0.0001 par value per share) AT-THE-MARKET EQUITY OFFERING SALES AGREEMENT (Filed With SEC on July 3, 2013)
- 4,950,495 Shares of Common Stock par value $0.0001 742,574 Over-Allotment Shares SAREPTA THERAPEUTICS, INC. UNDERWRITING AGREEMENT (Filed With SEC on December 18, 2012)
- SAREPTA THERAPEUTICS, INC. Common Stock ($0.0001 par value per share) AT-THE-MARKET EQUITY OFFERING SALES AGREEMENT (Filed With SEC on September 4, 2012)
- 13. THIS ITEM ONLY APPLIES TO MODIFICATION OFCONTRACTS/ORDERS. IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14. (Filed With SEC on November 8, 2011)
- AVI BIOPHARMA, INC. STAND ALONE STOCK OPTION GRANT NOTICE OF GRANT OF STOCK OPTION (Filed With SEC on May 10, 2011)
- 20,000,000 Shares of Common Stock par value $0.0001 3,000,000 Over-Allotment Shares AVI BIOPHARMA, INC. UNDERWRITING AGREEMENT (Filed With SEC on April 1, 2011)
- COMMON STOCK PURCHASE WARRANT AVI BIOPHARMA, INC. (Filed With SEC on August 24, 2009)
- AVI BioPharma, Inc. UNDERWRITING AGREEMENT (Filed With SEC on August 24, 2009)
- SEVERANCEAND RELEASE AGREEMENT (Filed With SEC on March 10, 2009)